Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
--
Revenue (TTM)
--
Net Profit (TTM)
--
ROE
--
ROCE
--
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
EV/EBITDA
--
Div. Yield
--
Debt to Equity
--
Book Value
--
EPS
--
Face value
--
Shares outstanding
--
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
SomaLogic Inc. Warrant (SLGCW)
| -28.3 | -44.2 | -52.2 | -80.5 | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
|---|---|
|
SomaLogic Inc. Warrant (SLGCW)
| -70.0 |
|
S&P Small-Cap 600
| 13.9 |
|
BSE Sensex
| 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific... for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado. Read more
Exec. Chairman
Mr. Troy M. Cox M.B.A.
Exec. Chairman
Mr. Troy M. Cox M.B.A.
Headquarters
Boulder, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of SomaLogic Inc Warrant (SLGCW) is $0.09 (NASDAQ) as of 05-Jan-2024 15:52 EDT. SomaLogic Inc Warrant (SLGCW) has given a return of -80.45% in the last 1 years.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.68
|
0.13
|
|
2021
|
-7.02
|
0.99
|
|
2020
|
--
|
--
|
|
2022
|
-0.68
|
0.13
|
|
2021
|
-7.02
|
0.99
|
The 52-week high and low of SomaLogic Inc Warrant (SLGCW) are Rs -- and Rs -- as of 04-Apr-2026.
SomaLogic Inc Warrant (SLGCW) has a market capitalisation of -- as on 25-Jan-2024. As per SEBI classification, it is a Small Cap company.
Before investing in SomaLogic Inc Warrant (SLGCW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.03
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.